Combination Chemotherapy in Treating Patients With Multiple Myeloma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentCompleted18 and overOtherMY7
CAN-NCIC-MY7, NCI-V95-0713, CDR0000064328, NCT00002678

Trial Description


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with multiple myeloma.

PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients with multiple myeloma.

Further Study Information


  • Compare the overall survival of patients with previously untreated stage I-III multiple myelome treated with melphalan combined with dexamethasone or prednisone as induction therapy.
  • Compare the overall survival of patients with stable or responding disease after induction treated with dexamethasone vs observation alone as maintenance therapy.
  • Compare the time to progression, response rate, and quality of life of patients treated with these regimens.
  • Compare the toxic effects of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, stage (I or II vs III), creatinine (less than 2.0 mg/dL vs 2.0 mg/dL or greater), and intention to use prophylactic bisphosphonate (yes vs no).

  • Induction: Patients are randomized to 1 of 4 treatment arms.
  • Arms I and II: Patients receive induction comprising oral prednisone followed by oral melphalan on days 1-4.
  • Arms III and IV: Patients receive induction comprising oral melphalan and oral dexamethasone (DM) on days 1-4 of all courses and DM on days 15-18 of courses 1-3.

Induction for arms I-IV continues every 4 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease after induction proceed to maintenance therapy.

  • Maintenance:
  • Arms I and III: Patients undergo observation.
  • Arms II and IV: Patients receive oral DM on days 1-4. Maintenance therapy continues every 4 weeks for arms II and IV and every 3 months for arms I and III in the absence of disease progression or unacceptable toxicity. Patients on arms I-IV who develop disease progression proceed to reinduction.
  • Reinduction: Patients restart induction on the arm to which they were originally randomized. Reinduction continues every 4 weeks in the absence of stable response lasting 16 weeks, disease progression, or unacceptable toxicity. Patients who achieve a stable response lasting 16 weeks restart maintenance therapy. Patients who experience further disease progression during reinduction are taken off study.

Quality of life is assessed at baseline, on day 1 of courses 1-3 and then every 3 courses during induction, and then every 3 months during maintenance therapy.

Patients are followed every 6 months.

PROJECTED ACCRUAL: A maximum of 600 patients will be accrued for this study within 6 years.

Eligibility Criteria


  • Histologically proven previously untreated stage I-III multiple myeloma
  • Patients with stage I disease must be symptomatic
  • Must meet at least 1 of the following conditions:
  • Plasma cells in osteolytic lesion or soft tissue tumor biopsy
  • At least 10% plasmacytosis in bone marrow aspirate and/or biopsy
  • Less than 10% plasma cells in bone marrow but at least 1 bony lesion
  • Detectable serum M-component of IgG, IgA, IgD, or IgE
  • If only light chain disease (urine M-protein) present, urinary excretion of light chain (Bence Jones) protein must be at least 1.0 g/24 hours



  • 18 and over

Performance status:

  • ECOG 0-4

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No other concurrent serious illness
  • Concurrent diabetes allowed, at the discretion of the treating physician, if changes in insulin requirements can be managed
  • No other prior or concurrent malignancy except curatively treated nonmelanomatous skin cancer or carcinoma in situ of the cervix


Biologic therapy:

  • No concurrent immunizations
  • No concurrent filgrastim (G-CSF) or other growth factors as prophylaxis
  • Concurrent epoetin alfa for anemia allowed


  • No prior chemotherapy

Endocrine therapy:

  • Prior dexamethasone or prednisone with radiotherapy for spinal cord compression allowed if cumulative dexamethasone dose no greater than 120 mg and cumulative prednisone dose no greater than 792 mg
  • Prior or concurrent corticosteroids for hypercalcemia allowed


  • See Endocrine therapy
  • Prior focal radiotherapy allowed
  • Concurrent focal radiotherapy during induction allowed
  • Concurrent radiotherapy for palliation (e.g., painful osteolytic lesions or spinal cord compression) allowed


  • At least 2 years since prior surgery for radiologic or endoscopic diagnosis of gastric or duodenal ulcer


  • At least 2 years since prior medication for radiologic or endoscopic diagnosis of gastric or duodenal ulcer
  • Prior or concurrent bisphosphonates for hypercalcemia allowed

Trial Contact Information

Trial Lead Organizations/Sponsors

NCIC-Clinical Trials Group

    Chaim Shustik, Study Chair

    Link to the current record.
    NLM Identifier NCT00002678 processed this data on April 09, 2015

    Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to